Navigation Links
Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
Date:10/21/2009

SEATTLE, Oct. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today the results from its Annual Meeting of Shareholders held on Tuesday, October 20, 2009.

At the meeting, shareholders elected Mr. Richard L. Love, Dr. Mary O. Mundinger, and Dr. Jack W. Singer to serve on the Company's Board of Directors until the 2012 Annual Meeting. Shareholders approved the proposals to increase the number of shares available for issuance under its 2007 Equity Incentive Plan, increase the number of shares available for issuance under its 2007 Employee Purchase Plan and issue shares of common stock in lieu of future milestone payments related to the Company's drug candidate brostallicin. Shareholders ratified the selection of Stonefield Josephson, Inc. as the Company's independent auditors for the year ending December 31, 2009.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, the Company does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


    Media Contact:
    Cell Therapeutics, Inc.
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    Lindsey Jesch
    T: 206.272.4347
    F: 206.272.4434
    E: deramian@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Cell Therapeutics, Inc.
    Ed Bell
    T: 206.272.4345
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


SOURCE Cell Therapeutics, Inc.


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... Ind. , Sept. 1, 2017  Explorers Like Us ... capture America,s greatest aural experiences — and deliver these experiences ... experience to help people feel and heal better. ... While nothing beats a ... and refresh your mind, Life Environments™ is the next best ...
(Date:8/31/2017)... Aug. 31, 2017 PM360,s annual Innovations ... to the latest innovations happening across the industry. Established ... to focus on providing a comprehensive look at the ... covers the most innovative companies, startups, divisions, products, services, ... "Everyone in this industry wants to ...
(Date:8/29/2017)... In a move that promises to exponentially ... veterinary practices of all sizes, Cubex LLC and The ... TITAN,s expertise in physical security, drug diversion investigations, staff ... "Every veterinary ... is at risk today," said TITAN founder and CEO, ...
Breaking Medicine Technology:
(Date:9/19/2017)... , ... September 19, 2017 , ... Public outrage over ... pollutants have fallen on deaf ears, leaving the water industry itself to research, develop ... stays ahead of the curve in the field of natural alkaline water ...
(Date:9/19/2017)... ... ... Bone Solutions Inc. (BSI), an orthobiologics technology company located ... OsteoCrete® bone void filler is designed to assist with bone repair and generation, ... for bone health and development. , “We’re excited to bring this important orthopedic ...
(Date:9/19/2017)... ... September 19, 2017 , ... Ron Norman, CEO of ... the importance of making a distinct rather than generic impression in the job market ... look through a stack of resumes knows that the first impression they give off ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency ... the Certified Emergency Nurse (CEN®) certification according to a large-scale study ... of certification study, conducted by the Human Resources Research Organization (HumRRO) in late ...
(Date:9/18/2017)... ... 2017 , ... A September 7 article on BBC News describes ... the world’s most common and least expensive medications, may be able to stimulate stem ... of California Dental Group and Calabasas Dental Care says that, while it’s likely to ...
Breaking Medicine News(10 mins):